Abstract
The standard treatment for patients with bladder cancer is surgical transurethral resection (TUR). Intravesical chemotherapy and immunotherapy are widely used after TUR to prevent recurrence and progression of superficial disease. There are many drug therapies for bladder cancer via intravesical instillation. This review describes the drugs which are approved or currently tested for treating bladder cancers. Some new chemotherapies and immunotherapies under investigation are also introduced. Vehicles to carry or encapsulate intravesical drugs are introduced in this review. Enhancement approaches to promote drug absorption or prolong residence times such as nano-sized particles, thermo-chemotherapy, and electromotive drug administration are also discussed. This review summarizes the information regarding intravesical therapy and its enhancement techniques. Recent developments of these drugs and their carriers for in vivo or clinical use are presented.
Keywords: Intravesical delivery, bladder cancer, chemotherapy, immunotherapy
Current Drug Delivery
Title: Intravesical Drug Delivery into the Bladder to Treat Cancers
Volume: 6 Issue: 3
Author(s): Jia-You Fang and Zih-Rou Huang
Affiliation:
Keywords: Intravesical delivery, bladder cancer, chemotherapy, immunotherapy
Abstract: The standard treatment for patients with bladder cancer is surgical transurethral resection (TUR). Intravesical chemotherapy and immunotherapy are widely used after TUR to prevent recurrence and progression of superficial disease. There are many drug therapies for bladder cancer via intravesical instillation. This review describes the drugs which are approved or currently tested for treating bladder cancers. Some new chemotherapies and immunotherapies under investigation are also introduced. Vehicles to carry or encapsulate intravesical drugs are introduced in this review. Enhancement approaches to promote drug absorption or prolong residence times such as nano-sized particles, thermo-chemotherapy, and electromotive drug administration are also discussed. This review summarizes the information regarding intravesical therapy and its enhancement techniques. Recent developments of these drugs and their carriers for in vivo or clinical use are presented.
Export Options
About this article
Cite this article as:
Fang Jia-You and Huang Zih-Rou, Intravesical Drug Delivery into the Bladder to Treat Cancers, Current Drug Delivery 2009; 6 (3) . https://dx.doi.org/10.2174/156720109788680868
DOI https://dx.doi.org/10.2174/156720109788680868 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Therapeutic Potential of ADAM15
Current Pharmaceutical Design A Review on Synthetic and Natural Steroid Dimers: 1997-2006
Current Medicinal Chemistry QbD Approach For Anti-Cancer Drugs - A Review
Current Pharmaceutical Analysis Current Prospects of Synthetic Curcumin Analogs and Chalcone Derivatives Against Mycobacterium Tuberculosis
Medicinal Chemistry Anti-Cancer Therapy: Targeting the Mevalonate Pathway
Current Cancer Drug Targets Network Pharmacology-based Prediction and Verification of Shikonin for Treating Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Chinese Medicinal Herbs as Source of Antioxidant Compounds – Where Tradition Meets the Future
Current Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Overactive Bladder - Current Treatment Modalities
Current Women`s Health Reviews Combined Cancer Therapy with Non-Conventional Drugs: All Roads Lead to AMPK
Mini-Reviews in Medicinal Chemistry Development of Specific New ELISA for Bioanalysis of Cetuximab: A Monoclonal Antibody Used for Cancer Immunotherapy
Current Pharmaceutical Analysis Alternative Spliced Variants as Biomarkers of Colorectal Cancer
Current Drug Metabolism Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Editorial (Mini-Thematic Issue: Morphological and Molecular Backgrounds for Personalized Therapies in Genitourinary Cancers)
Current Drug Targets Prostatic Tumor Stroma: A Key Player in Cancer Progression
Current Cancer Drug Targets Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives
Current Topics in Medicinal Chemistry The Therapeutic Potential of Neuro-EPO Administered Nasally on Acute Cerebrovascular Disease
Current Psychopharmacology